HairMax LaserBand 82 Promises 90‑Second Treatments as Company Cites Clinical Gains
HairMax promotes FDA clearance and clinical study results for its 82‑laser headband as red‑light therapy devices gain traction; the product is offered in a limited Amazon promotion
HairMax is marketing its LaserBand 82 ComfortFlex as a medical‑grade red‑light device that can produce visible hair growth with 90‑second sessions three times a week, pointing to clinical studies and physician endorsements to support the claim.
The company said a six‑month study of the device showed 93 percent of participants experienced significant hair growth, with an average increase of 129 new hairs per square inch. HairMax also said most users see visible results in three to six months, while noting individual outcomes vary. The device is currently listed in a limited promotion on Amazon through Sept. 30 using a manufacturer code.
The LaserBand 82 ComfortFlex uses 82 medical‑grade lasers arranged across a flexible headband designed to distribute low‑level laser light energy directly to hair follicles, the company said. The band includes soft teeth to spread hair during treatment and a timer set for 90‑second sessions. HairMax describes the device as FDA‑approved and says it is doctor‑recommended for people with hereditary hair loss, male or female pattern hair loss, menopause‑related thinning and age‑related hair thinning.
"There's a noticeable difference in patients who use HairMax after hair transplantation and those who don't," said Dr. Nader Ronaghi, a hair transplant surgeon quoted by the company. "Patients see results quicker, and they also see better results." The company also shared user accounts praising fuller hair and other changes after prolonged use.
Red‑light therapy, also called low‑level laser therapy (LLLT), has grown in popularity in recent years as a noninvasive option for addressing hair thinning. HairMax, founded in 2000, has been a prominent manufacturer of at‑home and clinic devices that use LLLT and has previously sought regulatory clearance for its products.
Clinical trial results and company success rates vary by study and by device. HairMax's materials cite an "over 90 percent success rate in clinical studies" and highlight the six‑month trial referenced above. The company also includes standard caveats that results vary by individual and that consistent use is required to achieve the outcomes reported in trials.
LLLT devices are often positioned alongside other established hair‑loss treatments such as topical minoxidil, oral finasteride and surgical hair transplantation. Physicians and patients typically consider factors including cause of hair loss, medical history and treatment goals when selecting an approach. HairMax and other manufacturers recommend consulting a health professional before beginning any new treatment regimen.
The current promotional listing on Amazon offers a temporary discount when shoppers enter code KCKQ2ZRS at checkout through Sept. 30, according to the company. HairMax continues to present the LaserBand 82 as a short‑duration, at‑home treatment option for people seeking to prevent or reverse pattern and age‑related hair thinning, while emphasizing clinical study results and physician support in its marketing materials.